Advicenne S.A. (FRA:3MM)

Market Cap	15.57M -27.0%
Revenue (ttm)	6.40M +21.6%
Net Income	-9.53M
EPS	-0.65
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.010
Previous Close	1.008
Day's Range	1.010 - 1.048
52-Week Range	0.808 - 2.200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 11
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3MM

Financial Performance

In 2025, Advicenne's revenue was 6.40 million, an increase of 21.56% compared to the previous year's 5.27 million. Losses were -9.53 million, 47.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error